Importantly, our study has defined the clinical context in which EHMT2, EHMT1 together with EZH2 are expressed at high levels, mostly MYCN-amplified high-risk NBs with a T-cell-poor and non-inflamed TME phenotype. This evidence concerns the gene MYCN and Nijmegen breakage syndrome.